Portal de Periódicos da CAPES

68 Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study

2018; Lippincott Williams & Wilkins; Volume: 200; Issue: 1 Linguagem: Inglês

10.1016/j.juro.2018.01.079

1527-3792

Egesta Lopci, Alberto Saita, Massimo Lazzeri, Giovanni Lughezzani, Piergiuseppe Colombo, Nicolò Maria Buffi, Rodolfo Hurle, Katia Marzo, Roberto Peschechera, Alessio Benetti, Silvia Zandegiacomo, Luisa Pasini, Giuliana Lista, Pasquale Cardone, Angelo Castello, Davide Maffei, Luca Balzarini, Arturo Chiti, Giorgio Guazzoni, Paolo Casale,

Molecular Biology Techniques and Applications

No AccessJournal of UrologyAdult Urology1 Jul 201868Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study Egesta Lopci, Alberto Saita, Massimo Lazzeri, Giovanni Lughezzani, Piergiuseppe Colombo, Nicolò Maria Buffi, Rodolfo Hurle, Katia Marzo, Roberto Peschechera, Alessio Benetti, Silvia Zandegiacomo, Luisa Pasini, Giuliana Lista, Pasquale Cardone, Angelo Castello, Davide Maffei, Luca Balzarini, Arturo Chiti, Giorgio Guazzoni, and Paolo Casale Egesta LopciEgesta Lopci Nuclear Medicine Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Alberto SaitaAlberto Saita Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Massimo LazzeriMassimo Lazzeri Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Giovanni LughezzaniGiovanni Lughezzani Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Piergiuseppe ColomboPiergiuseppe Colombo Pathology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Nicolò Maria BuffiNicolò Maria Buffi Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Rodolfo HurleRodolfo Hurle Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Katia MarzoKatia Marzo Nuclear Medicine Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Roberto PeschecheraRoberto Peschechera Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Alessio BenettiAlessio Benetti Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Silvia ZandegiacomoSilvia Zandegiacomo Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Luisa PasiniLuisa Pasini Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Giuliana ListaGiuliana Lista Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Pasquale CardonePasquale Cardone Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Angelo CastelloAngelo Castello Nuclear Medicine Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Davide MaffeiDavide Maffei Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Luca BalzariniLuca Balzarini Radiology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author , Arturo ChitiArturo Chiti Nuclear Medicine Department, Humanitas Clinical and Research Hospital, Milan, Italy Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy Pathology Department, Humanitas Clinical and Research Hospital, Milan, Italy Radiology Department, Humanitas Clinical and Research Hospital, Milan, Italy Humanitas University, Milan, Italy More articles by this author , Giorgio GuazzoniGiorgio Guazzoni Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy Pathology Department, Humanitas Clinical and Research Hospital, Milan, Italy Radiology Department, Humanitas Clinical and Research Hospital, Milan, Italy Humanitas University, Milan, Italy More articles by this author , and Paolo CasalePaolo Casale Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.01.079AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography may represent the most promising imaging modality to identify and risk stratify prostate cancer in patients with contraindications to or negative multiparametric magnetic resonance imaging. Materials and Methods: In this prospective observational study we analyzed 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography in a select group of patients with persistently elevated prostate specific antigen and/or Prostate Health Index suspicious for prostate cancer, negative digital rectal examination and at least 1 negative biopsy. The cohort comprised men with equivocal multiparametric magnetic resonance imaging (Prostate Imaging-Reporting and Data System, version 2 score of 2 or less), or an absolute or relative contraindication to multiparametric magnetic resonance imaging. Sensitivity, specificity and CIs were calculated compared to histopathology findings. ROC analysis was applied to determine the optimal cutoff values of 68Ga labeled prostate specific membrane antigen uptake to identify clinically significant prostate cancer (Gleason score 7 or greater). Results: A total of 45 patients with a median age of 64 years were referred for 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography between January and August 2017. The 25 patients (55.5%) considered to have positive positron emission tomography results underwent software assisted fusion biopsy. We determined the uptake values of regions of interest, including a median maximum standardized uptake value of 5.34 (range 2.25 to 30.41) and a maximum-to-background standardized uptake value ratio of 1.99 (range 1.06 to 14.42). Mean and median uptake values on 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography (ie the maximum standardized uptake value or the maximum-to-background standardized uptake value ratio) were significantly higher for Gleason score 7 lesions than for Gleason score 6 or benign lesions (p <0.001). On ROC analysis a maximum standardized uptake value of 5.4 and a maximum-to-background standardized uptake value ratio of 2 discriminated clinically relevant prostate cancer with 100% overall sensitivity in each case, and 76% and 88% specificity, respectively. Conclusions: Our findings support the use of 68Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography for primary detection of prostate cancer in a specific subset of men. References 1 : Global cancer statistics. CA Cancer J Clin2011; 61: 69. Google Scholar 2 : Prostate cancer. Lancet2016; 387: 70. Google Scholar 3 : Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy. Eur Urol2015; 68: 438. Google Scholar 4 : Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol2015; 67: 569. Google Scholar 5 : Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging2007; 34: 45. Google Scholar 6 : Molecular imaging and precision medicine in prostate cancer. PET Clin2017; 12: 83. Google Scholar 7 : Re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol2016; 70: e112. Google Scholar 8 : Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance imaging in localized prostate cancer. J Urol2016; 196: 1261. Link, Google Scholar 9 : Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel)2014; 7: 779. Google Scholar 10 : (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. Eur J Nucl Med Mol Imaging2015; 42: 1284. Google Scholar 11 : Simplified NaCl based (68)Ga concentration and labeling procedure for rapid synthesis of (68)Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem2012; 23: 1712. Google Scholar 12 : Targeted PET/TRUS software fusion-guided biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy: a feasibility study and preliminary results. Eur Urol2016; 15: e505. Google Scholar 13 : Targeted 11C-choline PET-CT/TRUS software fusion guided prostate biopsy in men with persistently elevated PSA and negative mpMRI or MRI contraindications after previous negative biopsy. Eur J Hybrid Imaging2017; 1: 9. Google Scholar 14 : Multimodal image-guided prostate fusion biopsy based on automatic deformable registration. Int J Comput Assist Radiol Surg2015; 10: 1997. Google Scholar 15 : EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol2017; 71: 618. Google Scholar 16 : Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer2016; 122: 884. Google Scholar 17 : Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol2016; 70: 926. Google Scholar 18 : Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer1998; 82: 2256. Google Scholar 19 : 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus2016; 10.1016/j.euf.2016.11.002. Crossref, Google Scholar 20 : Immunohistochemical validation of PSMA-expression measured by 68Ga-PSMA PET/CT in primary prostate cancer. J Nucl Med2017; 10.1016/j.euf.2016.11.002. Crossref, Google Scholar 21 : 68Ga-PSMA-11 PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med2017; 58: 1943. Google Scholar 22 : Intra-individual comparison of 18F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer—a retrospective, proof of concept study. J Nucl Med2017; 58: 1805. Google Scholar 23 : Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer. J Nucl Med2016; 57: 563. Google Scholar 24 : 68Ga-PSMA-HBED-CC PET/CT detects location and extent of primary prostate cancer. J Nucl Med2016; 57: 1720. Google Scholar 25 : Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol2016; 70: 829. Google Scholar 26 : Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol2015; 17: 565. Google Scholar 27 : Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol2015; 17: 575. Google Scholar 28 : F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging2017; 44: 678. Google Scholar 29 : Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging2016; 43: 1400. Google Scholar 30 : Comparison of 68Ga-HBED-CC PSMAPET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics2017; 7: 228. Google Scholar © 2018 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 200Issue 1July 2018Page: 95-103 Advertisement Copyright & Permissions© 2018 by American Urological Association Education and Research, Inc.Keywordsglutamate carboxypeptidase IIdiagnostic imagingprostatic neoplasmshumanbiopsypositron emission tomography computed tomographyMetricsAuthor Information Egesta Lopci Nuclear Medicine Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Alberto Saita Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Massimo Lazzeri Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Giovanni Lughezzani Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Piergiuseppe Colombo Pathology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Nicolò Maria Buffi Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Rodolfo Hurle Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Katia Marzo Nuclear Medicine Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Roberto Peschechera Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Alessio Benetti Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Silvia Zandegiacomo Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Luisa Pasini Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Giuliana Lista Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Pasquale Cardone Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Angelo Castello Nuclear Medicine Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Davide Maffei Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Luca Balzarini Radiology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Arturo Chiti Nuclear Medicine Department, Humanitas Clinical and Research Hospital, Milan, Italy Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy Pathology Department, Humanitas Clinical and Research Hospital, Milan, Italy Radiology Department, Humanitas Clinical and Research Hospital, Milan, Italy Humanitas University, Milan, Italy More articles by this author Giorgio Guazzoni Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy Pathology Department, Humanitas Clinical and Research Hospital, Milan, Italy Radiology Department, Humanitas Clinical and Research Hospital, Milan, Italy Humanitas University, Milan, Italy More articles by this author Paolo Casale Urology Department, Humanitas Clinical and Research Hospital, Milan, Italy More articles by this author Expand All Advertisement PDF downloadLoading ...